miR‐181a overexpression predicts the poor treatment response and early‐progression of serous ovarian cancer patients
暂无分享，去创建一个
A. Scorilas | E. Obermayr | R. Zeillinger | I. Vergote | V. Magdolen | J. Sehouli | M. Avgeris | A. Reinthaller | I. Braicu | S. Mahner | J. Dorn | K. Mavridis | K. Michaelidou | K. Panoutsopoulou | T. Dreyer | L. Loverix | Paraskevi Magkou